Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2

Rajnish A. Gupta, Raymond N. DuBois

Research output: Contribution to journalArticle

873 Citations (Scopus)

Abstract

Population-based studies have established that long-term intake of non-steroidal anti-inflammatory drugs (NSAIDs), compounds that inhibit the enzymatic activity of cyclooxygenase (COX), reduces the relative risk for developing colorectal cancer. These studies led to the identification of a molecular target, COX-2, that is involved in tumour promotion during colorectal cancer progression. Recent studies in humans indicate that therapy with specific COX-2 inhibitors might be an effective approach to colorectal cancer prevention and treatment.

Original languageEnglish (US)
Pages (from-to)11-21
Number of pages11
JournalNature Reviews Cancer
Volume1
Issue number1
StatePublished - 2001
Externally publishedYes

Fingerprint

Cyclooxygenase 2
Colorectal Neoplasms
Cyclooxygenase 2 Inhibitors
Prostaglandin-Endoperoxide Synthases
Anti-Inflammatory Agents
Pharmaceutical Preparations
Population
Neoplasms
Therapeutics

ASJC Scopus subject areas

  • Cancer Research

Cite this

Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. / Gupta, Rajnish A.; DuBois, Raymond N.

In: Nature Reviews Cancer, Vol. 1, No. 1, 2001, p. 11-21.

Research output: Contribution to journalArticle

Gupta, Rajnish A. ; DuBois, Raymond N. / Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. In: Nature Reviews Cancer. 2001 ; Vol. 1, No. 1. pp. 11-21.
@article{6cbc37662f284d77984b8bf4d375621d,
title = "Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2",
abstract = "Population-based studies have established that long-term intake of non-steroidal anti-inflammatory drugs (NSAIDs), compounds that inhibit the enzymatic activity of cyclooxygenase (COX), reduces the relative risk for developing colorectal cancer. These studies led to the identification of a molecular target, COX-2, that is involved in tumour promotion during colorectal cancer progression. Recent studies in humans indicate that therapy with specific COX-2 inhibitors might be an effective approach to colorectal cancer prevention and treatment.",
author = "Gupta, {Rajnish A.} and DuBois, {Raymond N.}",
year = "2001",
language = "English (US)",
volume = "1",
pages = "11--21",
journal = "Nature Reviews Cancer",
issn = "1474-175X",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2

AU - Gupta, Rajnish A.

AU - DuBois, Raymond N.

PY - 2001

Y1 - 2001

N2 - Population-based studies have established that long-term intake of non-steroidal anti-inflammatory drugs (NSAIDs), compounds that inhibit the enzymatic activity of cyclooxygenase (COX), reduces the relative risk for developing colorectal cancer. These studies led to the identification of a molecular target, COX-2, that is involved in tumour promotion during colorectal cancer progression. Recent studies in humans indicate that therapy with specific COX-2 inhibitors might be an effective approach to colorectal cancer prevention and treatment.

AB - Population-based studies have established that long-term intake of non-steroidal anti-inflammatory drugs (NSAIDs), compounds that inhibit the enzymatic activity of cyclooxygenase (COX), reduces the relative risk for developing colorectal cancer. These studies led to the identification of a molecular target, COX-2, that is involved in tumour promotion during colorectal cancer progression. Recent studies in humans indicate that therapy with specific COX-2 inhibitors might be an effective approach to colorectal cancer prevention and treatment.

UR - http://www.scopus.com/inward/record.url?scp=0035496616&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035496616&partnerID=8YFLogxK

M3 - Article

VL - 1

SP - 11

EP - 21

JO - Nature Reviews Cancer

JF - Nature Reviews Cancer

SN - 1474-175X

IS - 1

ER -